CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy

Inclusion Criteria: * Previously completed study protocol: o CLINICAL PROTOCOL to investigate the efficacy of recombinant human leptin (METRELEPTIN) in nonalcoholic steatohepatitis (NASH) or nonalcoholic fatty liver disease (NAFLD) associated with lipodystrophy, MB002-014 (IRMBED: HUM00058708) * Demonstrates clinical benefit as defined by meeting at least one of the following criteria upon completion of the above stated protocols: * Reduction of HbA1c ≥ 1.0% or, * Reduction of triglycerides ≥ 30% of baseline or, * Decrease in insulin requirements ≥ 40% or, * Reduction in total NASH score by ≥ 2 points, * Significant worsening of metabolic parameters after discontinuation of Metreleptin if discontinuation has been undertaken. * A health condition that appears to have significantly improved by metreleptin for which two independent health care providers make a request to prevent drug discontinuation. In addition, the PI has to document absence of contraindications for drug continuation (such as bone marrow suppression). * Is male or female ≥ 5 years old at baseline. * Is male, female not of childbearing potential, or meets all the following criteria if female of childbearing potential (including perimenopausal women who have had a menstrual period within one year): * Not breastfeeding * Negative pregnancy test result (human chorionic gonadotropin, beta subunit) at baseline (not applicable to hysterectomized females). * Must practice and be willing to cont…